Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Background The prognosis of patients with advanced biliary tract cancer who have
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …

Abstract “Financial toxicity” has now become a familiar term used in the discussion of cancer
drugs, and it is gaining traction in the literature given the high price of newer classes of …

Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Importance Approval by the US Food and Drug Administration of immune checkpoint
inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status …

PURPOSE It remains controversial whether primary tumor resection (PTR) before
chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic …

Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …